Figure 6

A03 shows a trend to increase SirT1 in 25-day oral study and increases SirT1 in Hip in 56-day study. (a) With 25-day oral dosing, there was a trend (p = 0.0805) for SirT1 to be increased by A03 treatment in the Hip (AU = Arbitrary Units; n = 12 for all groups). (b) Analysis by gender in the Hip did not reveal additional significance (n = 5 for females; n = 7 for males). (c) The increase in SirT1 in PtCx of E4FAD mice treated with A03 was not significant. (d) The results for FrCx were similar to those for PtCx. (e) In the longer 56-day study, there was a significant increase in SirT1 in the Hip with A03 (p = 0.0275; n = 13 for NTg Veh and n = 16 for E4FAD Veh and A03). (f) Analysis by gender showed the means for SirT1 in the Hip of both female and male A03-treated mice were higher than those for vehicle-treated mice and there was a trend to an increase (p = 0.0717) in the females. (g) There was no significant increase in SirT1 in the FrCx of A03-treated E4FAD mice. (h) Analysis by gender did not reveal further significance. All statistical analysis performed using two-tailed, unpaired t-tests for head-to-head comparisons of Veh- and A03-treated E4FAD mice only. Data graphed as the mean ± SEM.